SEC Tracker
Get the app

Lisata Therapeutics LSTA

Lisata Therapeutics reports $17M net loss

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Net loss of $17 million for the year ended Dec 31, 2025
  2. Acquired Marea Therapeutics on Sep 17, 2026
  3. Issued 1,793,129 shares of common stock to Marea shareholders

Written from the DEF 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Lisata Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Nanoviricides NNVC public float $24M, Dec 31, 2025
  2. Tenax Therapeutics TENX public float $24M, Jun 30, 2025
  3. Aytu Biopharma AYTU public float $24M, Dec 31, 2025
  4. Dyadic International DYAI public float $24M, Jun 30, 2025
  5. Kala Bio KALA public float $25M, Jun 30, 2025